Drug Insights

Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Lidocaine

27 February 2024
2 min read

Lidocainethe first amino amide–type local anesthetic (previous were amino esters),as opposed to the amino ester-type local anesthetics that were used before it, was originally called "xylocaine" . It works by blocking the sodium ion channels that are necessary for the initiation and conduction of nerve impulses. Lidocaine was first synthesized in 1943 by Nils Löfgren, a Swedish chemist. It was first marketed in 1947, and quickly became a widely used medicationIt indicated for the treatment of Ventricular tachycardia, Anesthesia,Neuralgia, Postherpetic,Hyperemesis Gravidarum. Click on the image below to begin the exploration journey of Lidocaine through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

NextPoint Therapeutics Begins Clinical Trial for NPX887 Targeting HHLA2+ Solid Tumors
Latest Hotspot
3 min read
NextPoint Therapeutics Begins Clinical Trial for NPX887 Targeting HHLA2+ Solid Tumors
27 February 2024
NextPoint Therapeutics Reveals Initiation of Early-Stage Clinical Study with First Subject Receiving NPX887 for Solid Tumors Containing HHLA2, an Innovative Treatment Aiming to Revitalize Worn-Out T and NK Cells.
Read →
Exploring Nivolumab's R&D successes and its clinical results at the 2024 ASCO_GU
Exploring Nivolumab's R&D successes and its clinical results at the 2024 ASCO_GU
27 February 2024
On Jan 25, 2024, new data comparing subcutaneous (SC) versus intravenous (IV) nivolumab in pre-treated advanced/metastatic ccRCC was unveiled at ASCO_GU 2024.
Read →
Nitroxoline: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GU
Nitroxoline: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GU
23 February 2024
APL-1202 (nitroxoline) is a reversible and orally available MetAP2 inhibitor with anti-angiogenic and anti-tumor activities.
Read →
FDA Grants Priority Review for argenx's VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
Latest Hotspot
3 min read
FDA Grants Priority Review for argenx's VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
23 February 2024
argenx has reported that the FDA has granted priority review status for their updated biologics application for VYVGART Hytrulo, aimed at treating chronic inflammatory demyelinating polyneuropathy.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.